Related Experiment Video

Updated: Dec 25, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.7K

The cardiovascular consequences of hyperaldosteronism

Gian Paolo Rossi1, Teresa Maria Seccia1, Giuseppe Maiolino1

  • 1Hypertension Unit, Department of Medicine, DIMED, University of Padova, Padova, Italy.

Annales D'Endocrinologie
|March 21, 2020
PubMed

Insights

Primary aldosteronism (PA), once deemed benign, significantly increases cardiovascular damage risk compared to essential hypertension. This review details cardiac and vascular changes in PA and discusses treatment impacts.

Area of Science:

  • Cardiology
  • Endocrinology
  • Hypertension Research

Background:

  • Primary aldosteronism (PA) is the most common secondary hypertension.
  • PA was historically considered benign but is now linked to increased cardiovascular damage.
  • Evidence shows PA patients experience greater cardiovascular harm than matched essential hypertensive patients.

Purpose of the Study:

  • To provide an updated review of cardiac and vascular changes in hyperaldosteronism.
  • To examine the link between hyperaldosteronism and resistant hypertension.
  • To discuss the effects of targeted PA treatment on cardiovascular alterations.

Main Methods:

  • Literature review of studies on primary aldosteronism.
  • Analysis of structural and electrical cardiac remodeling in PA.
  • Examination of vascular changes associated with hyperaldosteronism.

Main Results:

  • PA is associated with significant cardiovascular damage, exceeding that seen in essential hypertension.
  • Hyperaldosteronism contributes to cardiac remodeling and vascular alterations.
  • PA is frequently linked to resistant hypertension.

Conclusions:

  • Primary aldosteronism is a significant driver of cardiovascular damage and events.
  • Understanding PA's impact on cardiac and vascular health is crucial.
  • Targeted treatment of PA may mitigate cardiovascular risks.

Keywords:
AldosteroneCardiovascularHeartOrgan damage

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
819
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
597
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
735
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
626
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.1K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.5K